Satellite Symposia: New Horizons and Expert Insights on the Management of Recurrent Clostridioides difficile InfectionÊ

Society: DDW

Medscape Prorgam Description Clostridioides difficile causes a serious infection of the lower GI tract, resulting in significant morbidity and sometimes death. Standard antibiotics used to treat toxin-producing C. difficile do not kill the bacterial spores, which leaves patients susceptible to recurrent infections. Novel microbiome-directed biopharmaceutical products are now approved for the prevention of Clostridioides difficile infection (CDI) recurrence and represent a major paradigm shift in the management of CDI. In this hybrid live CME event, clinician experts will review the clinical data on these important new therapies and how they can be incorporated into clinical practice. The audience will have an opportunity to ask questions of the panel in both the live and virtual setting. Supporter Supported by an independent educational grant from Ferring Pharmaceuticals Inc. and Seres Therapeutics, Inc. & Aimmune Therapeutics CME For Physicians Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Creditsª. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ??For Pharmacists ?Medscape designates this continuing education activity for ?1.50? contact hour(s) (?0.150? CEUs) (Universal Activity Number: ?JA0007105-0000-23-124-L01-P?).